FDA Mulls Clearing Abilify Rival Based On Single Trial

By Jeff Overley (February 4, 2015, 6:09 PM EST) -- The U.S. Food and Drug Administration on Wednesday disclosed that it is considering whether to approve a competing version of blockbuster antipsychotic Abilify on the basis of a single clinical trial, a move that could have important implications for drugmaker profits.

The disclosure came in response to a citizen petition in which Abilify manufacturer Otsuka Pharmaceutical Co. Ltd. last year urged the FDA not accept or approve an application for a competing new drug from Alkermes PLC. Otsuka's rationale is that Alkermes only conducted a single stage III clinical trial and that its product doesn't qualify for any of the exceptions...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!